NCT05086445View on ClinicalTrials.gov

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

September 5, 2022

Study Completion Date

September 5, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3502970

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (5)

532-0003

Medical Corporation Heishinkai OPHAC Hospital, Osaka

192-0071

P-One Clinic, Hachiōji

162-0053

Clinical Research Hospital Tokyo, Shinjuku-ku

171-0014

Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic, Toshima City

232-0064

Yokohama Minoru Clinic, Yokohama

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05086445 - A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter